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BACKGROUND: Craniopharyngiomas are frequently diagnosed
hypothalamo-pituitary lesions in children where they present as predominant-
ly cystic lesions, lined by a secretory squamous epithelium. Morbidity associ-
ated with current therapeutic regimens has focussed attention towards
intracystic treatments as a mode of delivery, hypothesised to cause fewer clin-
ical consequences. However, the true efficacy of intracystic therapy remains
unclear. We report the retrospective experiences of several global centres in
using intracystic interferon-alpha. METHODS: All SIOP Europe and ISPN
centres were contacted to submit an anonymised datasheet capturing paediat-
ric patients in their care with a cystic craniopharyngioma that had received
intracystic interferon-alpha. Patient demographics, administration schedules,
adverse events and outcomes were captured. Progression was clinical or radio-
logical (cyst re-accumulation, novel cysts, or solid growth). RESULTS:
Fifty-five children (median age of 6.5 years) from over 20 international
centres were identified. Median follow-up was 5 years (0.3–17.7 years;
median 2.7 years post interferon). Lesions were either cystic (n ¼ 21; 38%)
or cystic/solid (n ¼ 34; 62%). Progression had been treated in 43 (78%) pa-
tientsprior to interferonuse. Progression wasdelayed by interferonwhencom-
pared to the preceding therapy for such patients (p ¼ 0.005), especially in
cystic cases (p ¼ 0.0001). Progression post interferon occurred in 40 patients
(median 14 months; 0–8 years). Few significant attributable side effects were
reported. CONCLUSION: Interferon-alpha appears to delay disease progres-
sion in paediatric craniopharyngioma and has a favourable toxicity profile
compared to other modalities, both important factors in this developing
age group. Prospective, randomised international clinical trial assessment is
warranted.
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